SNMMI: PSMA-PET helps guide prostate cancer therapy

ANAHEIM, CA - Adding an interim prostate-specific membrane antigen (PSMA)-PET...Read more on AuntMinnie.comRelated Reading: Could Ga-68 PSMA PET become essential for prostate cancer? Ga-68 PSMA PET/CT for prostate wins Australian favor Ga-68 PSMA-11 PET/MRI improves prostate cancer detection Novel nanoSPECT/CT radionuclide could aid cancer therapy SNMMI: Early prostate cancer therapy extends lives
Source: AuntMinnie.com Headlines - Category: Radiology Source Type: news

Related Links:

CONCLUSIONS: Sympathetic nerves innervating the tumor microenvironment promote cancer progression and are related to stress-induced cancer behavior. The parasympathetic/vagal nerves have variable (promoting or suppressing) effects on different cancer types. Approaches directed toward the sympathetic and parasympathetic/vagal nerves can be developed as a new cancer therapy. In addition to existing pharmacological, surgical, and electrical approaches, a recently developed virus vector-based genetic local neuroengineering technology is a powerful approach that selectively manipulates specific types of nerve fibers innervating...
Source: Clinical Prostate Cancer - Category: Cancer & Oncology Authors: Tags: Clin Auton Res Source Type: research
ConclusionsSympathetic nerves innervating the tumor microenvironment promote cancer progression and are related to stress-induced cancer behavior. The parasympathetic/vagal nerves have variable (promoting or suppressing) effects on different cancer types. Approaches directed toward the sympathetic and parasympathetic/vagal nerves can be developed as a new cancer therapy. In addition to existing pharmacological, surgical, and electrical approaches, a recently developed virus vector-based genetic local neuroengineering technology is a powerful approach that selectively manipulates specific types of nerve fibers innervating t...
Source: Clinical Autonomic Research - Category: Research Source Type: research
Abstract Prostate cancer is among the leading causes of death worldwide because its metastatic form is a deadly disease. Therefore, the development of new chemotherapeutics is of immense importance. Nanoparticle technology seems to provide diverse options in this regard. Therefore, poly(N-isopropylacrylamide) (PNIPAM) coated superparamagnetic iron oxide nanoparticles (SPION) loaded with etoposide were prepared in small sizes (57 nm) and with 3.5% drug content to improve the efficiency of etoposide in prostate cancer therapy. Sustained release of the drug was achieved, which found to be sensitive to low pH and high...
Source: Chemistry and Biodiversity - Category: Biochemistry Authors: Tags: Chem Biodivers Source Type: research
ACS Applied Materials&InterfacesDOI: 10.1021/acsami.0c11636
Source: ACS Applied Materials and Interfaces - Category: Materials Science Authors: Source Type: research
Susan Feyerabend Residual androgen production causes tumor progression in metastatic, castration-resistant prostate cancer (mCRPC) patients. Abiraterone acetate (AA), a prodrug of abiraterone, is an oral CYP-17 inhibitor that blocks androgen production. It was hypothesized that adherence-enhancing measures (AEM) might be beneficial for mCRPC patients receiving abiraterone acetate plus prednisone (AA + P). This multicenter, prospective, 2-arm trial allocated mCRPC patients who were progressive after docetaxel-based chemotherapy or asymptomatic/mildly symptomatic after failure of an androgen deprivation therapy to Arm ...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Article Source Type: research
Basel, 28 August 2020 - Roche (SIX: RO, ROG; OTCQX: RHHBY) today announced that the U.S. Food and Drug Administration (FDA) has approved FoundationOne ®Liquid CDx, Foundation Medicine’s comprehensive pan-tumour liquid biopsy test for patients with solid tumours. FoundationOne Liquid CDx is a comprehensive genomic profiling (CGP) test that analyses more than 300 cancer-related genes and multiple genomic signatures to optimise patient care. Cance r is a disease of the genome, driven by genetic mutations within a tumour’s DNA. CGP is used to identify these unique mutations to determine how a tumour behaves and...
Source: Roche Investor Update - Category: Pharmaceuticals Source Type: news
Authors: Filippi L, Chiaravalloti A, Schillaci O, Bagni O Abstract INTRODUCTION: Alpha emitters present several advantages for cancer therapy. The radiopharmaceutical 223Ra-dichloride has been recently introduced for the targeted alpha therapy (TAT) of metastastic castration-resistant prostate cancer (mCRPC). However, since 223Ra-dichloride targets only skeletal lesions, its use in clinical practice is recommended only in subjects without visceral metastases. To overcome this, several efforts have been made to develop radiopharmaceuticals suitable for TAT and specifically directed towards the biomarker prostate spe...
Source: Expert Review of Anticancer Therapy - Category: Cancer & Oncology Tags: Expert Rev Anticancer Ther Source Type: research
African Americans (AA) cancer survivors who smoked at diagnosis were less likely to report quitting if they lived with another smoker, had higher cumulative years of smoking, and a prostate cancer diagnosis. Individuals with higher social well ‐being scores were more likely to quit smoking. AbstractTobacco cessation among those recently diagnosed with cancer is important to improve their prognosis, yet, many cancer survivors continue to smoke. The epidemiology of tobacco use differs by race and ethnicity, and limited cessation research has been conducted in African American (AA) populations. Here, we assess demographic a...
Source: Cancer Medicine - Category: Cancer & Oncology Authors: Tags: ORIGINAL RESEARCH Source Type: research
Molecular PharmaceuticsDOI: 10.1021/acs.molpharmaceut.0c00457
Source: Molecular Pharmaceutics - Category: Drugs & Pharmacology Authors: Source Type: research
CD276 (also called B7-H3) is a pan-cancer antigen expressed in multiple solid tumors and an emerging cancer target. CD276 protein is overexpressed in pancreatic cancer, prostate cancer, breast cancer, colon cancer, lung cancer, and brain tumors (such as neuroblastoma) – making it an ideal target for cancer therapy. Investigators at the National Cancer Institute (NCI) have isolated a panel of anti-CD276 single domain antibodies (also known as nanobodies) from novel camel and rabbit single domain (VHH) libraries by phage display.  Nanobodies are the smallest known antigen-binding fragments of antibodies. Due ...
Source: NIH OTT Licensing Opportunities - Category: Research Authors: Source Type: research
More News: Australia Health | Cancer | Cancer & Oncology | Cancer Therapy | Nanotechnology | Prostate Cancer | Radiology